Prompt Diagnostics LLC, Maryland, US
https://prompt-dx.com/

Prompt is developing a diagnostic tool with high multiplexing capabilities that, if successful, detects multiple pathogenic bacteria including Neisseria gonorrhoeae (NG) and targets and their antibiotic susceptibility which will help to guide treatment at the point-of-care.

Gonorrhea, caused by Neisseria gonorrhoeae, is the second-most reported bacterial sexually transmitted infection, infecting approximately 82 million people globally in 2020, with the burden highest in LMICs. Patients with gonorrhea may experience serious health effects, including pelvic inflammatory disease, chronic pain, and infertility. Untreated gonorrhea can spread to the blood stream, which can be life threatening, and increase the risk of HIV infection. The true burden of gonorrhea may be greater than reported cases since patients do not always exhibit symptoms.

The CARB-X award supports focused attention on demonstrating feasibility to both detect gonorrhea and reliably characterize drug resistance through an array of genetic mutations, including those for third-generation cephalosporins. Their technology employs robust melt-curve analysis which could provide more options for reliable antibiotic susceptibility testing.

Current Development Stage: Feasibility

CARB-X Investment: US$1M

Initial CARB-X Investment Date: March 1, 2024